Diagnostic accuracy of point-of-care urine tenofovir test, and associations between metrics of tenofovir use and treatment outcomes in a community ART programme

BACKGROUND: Urine tenofovir (uTFV) and dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations respectively estimate short- and medium-term adherence to tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART). We evaluated the accuracy of a point-of-care uTFV assay, and associations between uTFV/TFV-DP, and viral load and retention outcomes within a South African community ART programme. METHODS: We measured uTFV and DBS TFV-DP concentrations using liquid chromatography-tandem mass spectrometry (LC-MS/MS). We calculated sensitivity and specificity of the point-of-care uTFV assay at the manufacturer-recommended threshold of ≥1500 ng/ml compared to LC-MS/MS. We assessed associations of the point-of-care uTFV assay, and DBS TFV-DP concentrations with concurrent viraemia, and with retention-in-care by 16weeks post-enrolment. RESULTS: Of 196 adults, median age was 44 years, 64.8% (127) were female, and 97.4% (191) were receiving TDF. One hundred and eighty-five (94.4%) had detectable point-of-care uTFV, which had high sensitivity (99.5%, 95% CI 96.5-100%) and moderate specificity (76.9%, 95% CI 46.0-93.8%) for detecting uTFV ≥1500 ng/ml. Two participants had concurrent viraemia ≥1000 copies/ml; of these 50.0% (1/2) (95% CI 9.4-90.5) had undetectable point-of-care uTFV, and 100% (2/2) (95% CI 19.7-100) had TFV-DP <483 fmol/punch. Among participants without viraemia, 97.4% (184/189) (95% CI 93.6-99.0) had detectable uTFV, and 98.4% (186/189) (95.3-99.6) had TFV-DP ≥483 fmol/punch. Point-of-care uTFV and DBS TFV-DP were not associated with retention-in-care. CONCLUSIONS: The point-of-care uTFV assay demonstrated high sensitivity and moderate specificity to detect uTFV. Over 95% of people without viraemia had detectable point-of-care uTFV or high DBS TFV-DP levels, respectively, but these were not associated with 16-week retention-in-care.

Authors

Institutions

Publication Details

Journal
AIDS
Published
2026-11-17
DOI
https://doi.org/10.1097/qad.0000000000004656
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Diagnostic accuracy of point-of-care urine tenofovir test, and associations between metrics of tenofovir use and treatment outcomes in a community ART programme

Yukteshwar Sookrajh, Nigel Garrett, Lara Lewis, Monica Gandhi et al.
2 links
AIDS
HIV/AIDS Research and Interventions
article

Diagnostic accuracy of point-of-care urine tenofovir test, and associations between metrics of tenofovir use and treatment outcomes in a community ART programme

Yukteshwar Sookrajh, Nigel Garrett, Lara Lewis, Monica Gandhi, Gail Hayward, Natasha Samsunder, Paul K. Drain, Pravi Moodley, Christopher Butler, Jienchi Dorward, Katya Govender, Johan S. van der Molen, Kwena Tlhaku, L.G.K. Naidu
article en

Abstract

BACKGROUND: Urine tenofovir (uTFV) and dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations respectively estimate short- and medium-term adherence to tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART). We evaluated the accuracy of a point-of-care uTFV assay, and associations between uTFV/TFV-DP, and viral load and retention outcomes within a South African community ART programme. METHODS: We measured uTFV and DBS TFV-DP concentrations using liquid chromatography-tandem mass spectrometry (LC-MS/MS). We calculated sensitivity and specificity of the point-of-care uTFV assay at the manufacturer-recommended threshold of ≥1500 ng/ml compared to LC-MS/MS. We assessed associations of the point-of-care uTFV assay, and DBS TFV-DP concentrations with concurrent viraemia, and with retention-in-care by 16weeks post-enrolment. RESULTS: Of 196 adults, median age was 44 years, 64.8% (127) were female, and 97.4% (191) were receiving TDF. One hundred and eighty-five (94.4%) had detectable point-of-care uTFV, which had high sensitivity (99.5%, 95% CI 96.5-100%) and moderate specificity (76.9%, 95% CI 46.0-93.8%) for detecting uTFV ≥1500 ng/ml. Two participants had concurrent viraemia ≥1000 copies/ml; of these 50.0% (1/2) (95% CI 9.4-90.5) had undetectable point-of-care uTFV, and 100% (2/2) (95% CI 19.7-100) had TFV-DP <483 fmol/punch. Among participants without viraemia, 97.4% (184/189) (95% CI 93.6-99.0) had detectable uTFV, and 98.4% (186/189) (95.3-99.6) had TFV-DP ≥483 fmol/punch. Point-of-care uTFV and DBS TFV-DP were not associated with retention-in-care. CONCLUSIONS: The point-of-care uTFV assay demonstrated high sensitivity and moderate specificity to detect uTFV. Over 95% of people without viraemia had detectable point-of-care uTFV or high DBS TFV-DP levels, respectively, but these were not associated with 16-week retention-in-care.

AIDS
University of Cape Town (ZA), University of California, San Francisco (US), Centre for the AIDS Programme of Research in South Africa (ZA), eThekwini Municipality (ZA), University of Oxford (GB), Africa Health Research Institute (ZA), University of KwaZulu-Natal (ZA)
Bill and Melinda Gates Foundation, Wellcome Trust, National Institute for Health and Care Research, Department of Health and Social Care, Dowager Countess Eleanor Peel Trust, National Institutes of Health, National Institute of Allergy and Infectious Diseases
Good health and well-being
HIV/AIDS Research and Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon